The director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a novel pharmacologic treatment that shows potential as an alternative to continuous positive airway pressure for sleep apnea. [WATCH TIME: 5 minutes]
The professor of materials science and engineering at Cornell University and chief executive officer at Artificial Axon Labs talked about the development of artificial axons through 3D printing. [WATCH TIME: 6 minutes]
Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences.
The associate professor of pediatrics at the University of Colorado School of Medicine talked at the 2023 MDA Conference about how digestive health impacts patients with Duchene Muscular Dystrophy. [WATCH TIME: 4 minutes]
The professor of emergency medicine at Washington University in St. Louis and associate professor of neurosurgery at UTHealth Houston talked about results from the phase 3 MOST trial assessing argatroban and eptifibatide in acute ischemic stroke. [WATCH TIME: 3 minutes]
The internal medicine physician and chief medical officer and head of development at Pear Therapeutics offered his perspective on the current focus that is given to sleep in clinical care and the lack of education on interventions. [WATCH TIME: 2 minutes]
The chief medical officer at Alzheon provided perspective on the next steps for ALZ-801 following a successful phase 2 study of patients with APOE ε4/4 or APOE ε3/4 genotype. [WATCH TIME: 2 minutes]
The head of Global Medical for Neuropsychiatry and Alzheimer Disease at Biogen commented on challenges with conducting effective trials for Alzheimer disease and the potential research opportunities with newly approved novel treatments. [WATCH TIME: 6 minutes]
As many as 1 in 3 infected with COVID-19 have longer-term neurological or mental health symptoms.
The chairman of the Clinical Advisory Committee of the New England Chapter of the National MS Society addressed the role DMTs play in patient response to the COVID-19 vaccine.
The clinical assistant professor of neurology at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, talked about her presentation on Evusheld at the 2023 ACTRIMS Forum. [WATCH TIME: 5 minutes]
The assistant director of computational biology at Stanford University discussed where the Alzheimer disease community stands on gene therapies that target APOE, and whether missense variants will play a role. [WATCH TIME: 4 minutes]
The movement disorders nurse practitioner at The Ohio State University Wexner Medical Center talked about a meeting that equips nurse practitioners and physician assistants to improve movement disorder patient care. [WATCH TIME: 5 minutes]
Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.
From Standard-of-Care Injectables to Next-Generation S1P Receptor Modulators, Newer Treatments Offer Patients Options
The chief executive officer at Parkinson & Movement Disorder Alliance and the president at PD Avengers discussed the importance of awareness in movement disorders and the challenges that patients still face in getting access to treatments for improved quality of life. [WATCH TIME: 12 minutes
The chief executive officer and founder at CureDuchenne discussed efforts to bring specialized physical therapy and infrastructure support to underserved regions to improve care for patients impacted by Duchenne worldwide. [WATCH TIME: 5 minutes]
The professor of neuroscience at Imperial College London talked about results from a study assessing a glucagon-like peptide-1 analogue, liraglutide, in patients with Alzheimer disease. [WATCH TIME: 5 minutes]
As the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.
The nurse practitioner at the Cleveland Clinic talked about findings from a recent study focused on enhancing medication management and education for patients with Parkinson disease. [WATCH TIME: 5 minutes]
Episode 23 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA and Albany Medical College; and Robert Holloway, MD, MPH, of University of Rochester School of Medicine and Dentistry. [WATCH TIME: 6 minutes]
A duo of experts discussed the importance of addressing barriers such as provider comfort, access to genetic counselors, and insurance coverage to reduce diagnostic latency and standardize genetic testing for epilepsy. [WATCH TIME: 5 minutes]
The neurologist at Lenox Hill Hospital detailed the findings of his observational study that looked at patterns of COVID-19 infections in patients with multiple sclerosis.
The professor of ophthalmology and neurology at Duke University School of Medicine talked about a recent published study on using artificial intelligence and retinal scans to detect mild cognitive impairment in neurodegenerative diseases including Alzheimer disease. [WATCH TIME: 7 minutes]
In honor of Insomnia Awareness Night, the president of the American Academy of Sleep Medicine board of directors talked about increasing awareness of the sleep disorder for the clinical and patient community. [WATCH TIME: 6 minutes]
The consultant neurologist at Fondazione Don Carlo Gnocchi ONLUS stressed how new clinical trial designs for cervical dystonia should incorporate more flexible and patient-centered approaches, including new measurement scales and the use of technology. [WATCH TIME: 5 minutes]
The director of the PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital talked about nasal administration of foralumab that shows promise in treating patients with non-active secondary progressive MS. [WATCH TIME: 5 minutes]
A trio of experts from university hospitals discussed a study that aimed to uncover the prevalence and associations of limb swelling in patients with Dravet syndrome in hopes of improving care. [WATCH TIME: 5 minutes]
The chief medical officer of Biohaven Pharmaceuticals discussed the findings of an assessment of rimegepant (Nurtec ODT) exposure with concomitant administration of inhibitors of P-gp and BCRP transporters.
Advanced practice practitioners share final pearls with their colleagues for the management of sleep disorders.